Mostrar el registro sencillo del ítem
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
| dc.contributor.author | Alunno, A. | |
| dc.contributor.author | Najm, A. | |
| dc.contributor.author | Machado, P. M. | |
| dc.contributor.author | Rodríguez Carrio, Javier | |
| dc.date.accessioned | 2021-06-29T08:58:41Z | |
| dc.date.available | 2021-06-29T08:58:41Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Annals of the Rheumatic Diseases, 80(6), p. 698-706 (2021); doi:10.1136/annrheumdis-2020-219724 | |
| dc.identifier.issn | 0003-4967 | |
| dc.identifier.uri | http://hdl.handle.net/10651/59324 | |
| dc.description.sponsorship | This work was funded by European League Against Rheumatism (CLI122). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). JDI is a NIHR Senior Investigator and his work is supported by the NIHR Newcastle Biomedical Research Centre in Ageing and Long- Term Conditions, and the Research Into Inflammatory Arthritis Centre versus Arthritis. AVR is a member of the paediatric steering committee of RECOVERY, the steering committee of COVINTOC study and the steering committee of baricitinib in COVID-19. | |
| dc.description.statementofresponsibility | Alunno, A., Najm, A., MacHado, P.M., Bertheussen, H., Burmester, G.R., Carubbi, F., De Marco, G., Giacomelli, R., Hermine, O., Isaacs, J.D., Koné-Paut, I., Magro-Checa, C., McInnes, I., Meroni, P.L., Quartuccio, L., Ramanan, A.V., Ramos-Casals, M., Carrio, J.R., Schulze-Koops, H., Stamm, T.A., Tas, S.W., Terrier, B., McGonagle, D.G., Mariette, X. | |
| dc.format.extent | p. 698-706 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Annals of the Rheumatic Diseases | |
| dc.rights | © 2021 Alunno et al. | |
| dc.rights | CC Reconocimiento - No Comercial - Sin Obra Derivada 4.0 Internacional | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Scopus | |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100543424&doi=10.1136%2fannrheumdis-2020-219724&partnerID=40&md5=c07155c24bcaa1fb9780d5b6d4f2e28d | |
| dc.title | EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 | |
| dc.type | journal article | |
| dc.identifier.doi | 10.1136/annrheumdis-2020-219724 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1136/annrheumdis-2020-219724 | |
| dc.rights.accessRights | open access | |
| dc.type.hasVersion | VoR |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [36141]
-
Biología Funcional [754]
Este ítem está sujeto a una licencia Creative Commons